In breast cancer, PTEN deficiency has been shown to activate, in a manner dependent on its protein phosphatase activity, the SRC proto-oncogene, non-receptor tyrosine kinase (SRC), thereby conferring resistance to human epidermal growth factor receptor 2 inhibition [19]. This evidence concerns the gene PTEN and breast carcinoma.